Leila Dardaei
Strategic Oncology Leader Driving Cross-Functional Teams to Discover Breakthrough Cancer Therapies
- Role
- Worldwide Commercial Oncology Early Asset Lead, Tod at Bristol Myers Squibb
- Location
- Boston, MA, US
- LinkedIn followers
- 500 followers
About Leila Dardaei
Dynamic and visionary leader in oncology drug discovery and translational research with over 15 years of extensive experience in both industry and academia. Renowned for expertise in target identification and validation, mechanistic cancer biology, biomarker discovery, patient stratification, and understanding therapeutic resistance mechanisms. Proven track record of leading and supporting cross-functional teams to advance programs from target discovery and validation through hit identification and lead optimization. Highly adept at forging impactful collaborations and leveraging data-driven methodologies to accelerate the discovery of transformative therapies. Strategic thinker with exceptional communication and leadership skills, consistently delivering innovative solutions to address unmet clinical needs and drive program success.
Experience
Worldwide Commercial Oncology Early Asset Lead, Tod
Aug 2025 — Present · Cambridge, MA, US
Education
Tarbiat Modares University
Master's Degree, Biology (Molecular Genetics)
2005 — 2008
University of Milan/European School of Molecular Medicine (SEMM)
Doctor of Philosophy (Ph.D.), Molecular Medicine (Molecular Oncology and Human Genetics)
2009 — 2012
Alzahra University
Bachelor's Degree, Microbiology
2001 — 2005
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.